首页> 外文期刊>Neuropharmacology >125I-Antisauvagine-30: a novel and specific high-affinity radioligand for the characterization of corticotropin-releasing factor type 2 receptors.
【24h】

125I-Antisauvagine-30: a novel and specific high-affinity radioligand for the characterization of corticotropin-releasing factor type 2 receptors.

机译:125I-Antisauvagine-30:一种新型的特异性高亲和力放射性配体,用于表征促肾上腺皮质激素释放因子2型受体。

获取原文
获取原文并翻译 | 示例
           

摘要

Corticotropin-releasing factor (CRF) receptors type 1 (CRF(1)) and type 2 (CRF(2)) differ from each other in their pharmacological properties. The human and ovine CRF versions bind to CRF(1) receptors with significantly higher affinity than to CRF(2) receptors. Recently antisauvagine-30, an N-terminally truncated version of the CRF analog sauvagine, was characterized as a specific antagonist to mouse CRF(2B). We have synthesized the radiolabeled version (125)I-antisauvagine-30 and tested it for its affinity at human CRF(1) (hCRF(1)), hCRF(2A), Xenopus CRF(1) (xCRF(1)) and xCRF(2) receptors. In control binding studies (125)I-labeled hCRF, sauvagine and astressin were also bound to these receptors. (125)I-antisauvagine-30 exclusively bound to hCRF(2A) and xCRF(2) but not to hCRF(1) and xCRF(1) receptors. (125)I-antisauvagine-30 binding to hCRF(2A) and xCRF(2) receptors was saturable and of high affinity (hCRF(2A): K(d)=125 pM; xCRF(2): K(d)=1.1 nM). In displacement binding experiments using (125)I-antisauvagine-30 as radioligand several CRF analogs bound to hCRF(2A) and xCRF(2) receptors with similar rank orders as reported with other CRF radioligands. Finally, preliminary studies using (125)I-antisauvagine-30 binding to membrane homogenates prepared from different rat brain structures showed that the peptide bound specifically to brain areas expressing CRF(2) receptors. These data demonstrate that (125)I-antisauvagine-30 is the first high-affinity ligand to specifically label CRF(2) receptors.
机译:1型(CRF(1))和2型(CRF(2))促肾上腺皮质激素释放因子(CRF)受体的药理特性彼此不同。人类和绵羊的CRF版本以比CRF(2)受体更高的亲和力与CRF(1)受体结合。最近,抗sauvagine-30(CRF类似物sauvagine的N端截短版本)被表征为小鼠CRF(2B)的特异性拮抗剂。我们已经合成了放射性标记的版本(125)I-antisauvagine-30,并对其在人CRF(1)(hCRF(1)),hCRF(2A),非洲爪蟾CRF(1)(xCRF(1))和xCRF(2)受体。在对照结合研究中(125)I标记的hCRF,鼠尾草素和astressin也与这些受体结合。 (125)I-antisauvagine-30仅与hCRF(2A)和xCRF(2)结合,但不与hCRF(1)和xCRF(1)受体结合。 (125)I-抗沙丁胺-30与hCRF(2A)和xCRF(2)受体的结合是可饱和的并且具有高亲和力(hCRF(2A):K(d)= 125 pM; xCRF(2):K(d)= 1.1 nM)。在置换结合实验中,使用(125)I-抗沙丁胺丙氨酸30作为放射性配体,与其他CRF放射性配体报道的具有相似秩序的hCRF(2A)和xCRF(2)受体结合了几种CRF类似物。最后,使用(125)I-抗沙丁胺丙氨酸30结合从不同大鼠脑结构制备的膜匀浆进行的初步研究表明,该肽特异性结合表达CRF(2)受体的脑区域。这些数据表明,(125)I-抗鸟嘌呤-30是第一个特异性标记CRF(2)受体的高亲和力配体。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号